May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
The Expression of Chondroitin Sulphate Glycosaminoglycans and Aggrecan Core Protein Epitopes in Young, Aged, and Glaucomatous Human Retinas
Author Affiliations & Notes
  • Y. Lei
    Cardiff University, Cardiff, United Kingdom
    Optometry and Vision Sciences,
  • B. Caterson
    Cardiff University, Cardiff, United Kingdom
    Bioscience,
  • D. Tudor
    Cardiff University, Cardiff, United Kingdom
    Optometry and Vision Sciences,
  • M. E. Boulton
    Ophthalmology & Visual Sciences, University of Texas Medical Branch, Galveston, Texas
  • M. P. Fautsch
    Mayo Clinic, Rochester, Minnesota
  • M. R. Hernandez
    Ophthalmology, Northwestern University, Chicago, Chicago, Illinois
  • J. E. Morgan
    Cardiff University, Cardiff, United Kingdom
    Optometry and Vision Sciences,
  • Footnotes
    Commercial Relationships  Y. Lei, None; B. Caterson, None; D. Tudor, None; M.E. Boulton, None; M.P. Fautsch, None; M.R. Hernandez, None; J.E. Morgan, None.
  • Footnotes
    Support  Research Into Ageing 127
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 761. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Lei, B. Caterson, D. Tudor, M. E. Boulton, M. P. Fautsch, M. R. Hernandez, J. E. Morgan; The Expression of Chondroitin Sulphate Glycosaminoglycans and Aggrecan Core Protein Epitopes in Young, Aged, and Glaucomatous Human Retinas. Invest. Ophthalmol. Vis. Sci. 2008;49(13):761. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The perineuronal net is one of the major hurdles which prevent neurons from regenerating and remodelling. To determine its importance in the repair of visual pathways, we compared the expression of chondroitin sulphate- glycosaminoglycans (CS-GAGs) and aggrecan core protein epitopes in young, aged and glaucomatous retinas.

Methods: : 12 human retinas were used in the study: young (18-33 yr, n=4), aged (60-85 yr, n=4) and glaucoma (67-89 yr, n=4). Retinal transverse sections were labelled using a range of monoclonal antibodies (mAbs) against CS-GAGs, keratan sulphated-GAGs (KS-GAGs), and aggrecan, decorin, biglycan, lumican, keratocan and versican core proteins, and analysed by immunohistochemistry.

Results: : CS-GAGs (0-, 4- & 6-sulphated) were detected as chondroitinase generated 'CS-stubs' using mAbs 1B5, 2B6 & 3B3 respectively, and aggrecan core protein using mAbs 6B4 and 7D1. All of these were expressed in three groups of retinas; the expression of 2B6 and 6B4 appeared to be up-regulated in the glaucoma group. Because only negative staining for decorin, biglycan, lumican, keratocan and versican was found, the major source of CS-GAG staining appears to be from aggrecan. Also, negative 5D4 staining suggests that this aggrecan in the retina is not or minimally substituted with KS-GAGs. In the interphotoreceptor matrix, the staining of CS-GAGs was co-localised with aggrecan core protein. Additionally, 6B4 and 7D1 were expressed in the inner retina, including the inner nucleus layers (INL), the inner plexiform layer (IPL), and the retinal ganglion cell layer (RGCL). This indicates that aggrecan core protein is expressed in these retinal tissue domains.

Conclusions: : This is the first report showing the difference between CS-GAG staining and aggrecan core protein staining in the human retina. It suggests that in the INL, IPL and RGCL the GAG attachment regions of aggrecan have been removed. The perineuronal net may inhibit the adult human retina from recovery following injury via their CS chains and/or aggrecan core protein.

Keywords: proteoglycans/glycosaminoglycans • retina • immunohistochemistry 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×